Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
about
Checkpoint Inhibitors and Their Application in Breast CancerMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerCurrent Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerStatistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practiceImmune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomesEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsThe molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant populationA phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerPrognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.Profiling networks of distinct immune-cells in tumors.An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer.The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltrationAssociation of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast CancerTaxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.Network-Based Enriched Gene Subnetwork Identification: A Game-Theoretic ApproachTumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.Eavesdropping on altered cell-to-cell signaling in cancer by secretome profilingImmunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness."Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patientsExpression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.HER2-positive breast cancer is lost in translation: time for patient-centered research.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces.
P2860
Q26745442-D0D93F0D-C30A-4B14-9648-300FE03DB8B4Q26752780-20A299AE-F673-403F-9FF9-A87735A87348Q26772969-5B084AFC-8689-439E-9361-28F23ABF7FEEQ26798074-E3AF7D4B-2828-4EFA-943D-3668D5A6ADD3Q28067145-5A9D7D5D-7D46-44B4-B86E-C3F92DE747E5Q28076490-A11ECEFD-D118-4422-9C3C-5B4B2208826EQ28078729-7D056E71-226E-4B43-BF75-24C72371A6C7Q33712476-644FEA09-957B-46EB-B04E-34D2E53A8793Q33717226-327E9CC2-C835-4FCE-857A-E889B98A852DQ33814856-4F78E930-C441-468A-810B-4EDBD0A0BA81Q33833475-E67BC848-0222-4C31-A1F5-256B3573E5CFQ33915044-90EA77E3-29C0-40F9-ACDB-538B68E441A7Q34532397-69F6BDA8-BC47-4442-99A7-657262F35B07Q35807188-D270D596-FFAC-43FC-8B59-5749D25BC14DQ36030405-39612703-B78B-4C4B-BFAC-0CEEF1B91334Q36067826-60CF1FB2-729A-40F2-8F84-0D76DA290CC2Q36085118-1EE092D4-05DC-44B0-AD46-05DDA2A210C5Q36110190-79F52FAE-CA59-4846-9170-EFBAFEE822C2Q36231343-944E827A-0A8F-4AA7-BF83-BD2A4418A55DQ36359705-6161C8D1-5A09-44D4-BA1B-ACD5F5E74CA4Q36414012-E193217A-156D-40DA-8A80-8F55FA63D19EQ36463604-A5FECF3F-FCC3-4673-8605-C59F980CB946Q36729376-B4926BB3-38C9-471C-947B-DBA8E36672F8Q36771143-6FF114F0-8D24-4925-B98F-7C57696AAD92Q36782680-9F50C3F2-25D0-4E72-B910-2750FAB6F351Q36836135-8A9E0E9D-49D0-4D33-BBD2-A24636F2B009Q37059747-16A83582-C46B-4D19-876D-6C6427554A4CQ37109643-DFC9FE1B-A7F2-4D13-8257-328BCE74385FQ37166436-94283441-AF7F-4AA0-8513-DE3FAD57D157Q37544396-4B578225-0BB4-48B5-8CE7-63128B81BFA9Q37547952-BF674DB3-4058-446D-84DA-B699201523BEQ38373249-A055810C-4057-4948-BAEA-C947CCAEDF6CQ38387030-37F0E044-E1E9-4E47-89B8-D3A64F4305CEQ38648765-B7E5AE49-DE0E-4BE0-826A-38E3F331E516Q38661390-0DA2FDB1-3C89-4F49-9667-3502A3D17EE3Q38786102-A12D8AF1-B1CC-42C5-B894-5BE531B5F4D3Q38823649-7F59FADC-729F-4CE2-9CA6-2856E34CC4A9Q38875037-FC7F21CD-40BD-47D2-9CC4-FE6CB080E007Q38948901-63467183-FA9F-4C9E-81A6-3360B0BE2B67Q39175273-8D52ED75-CF18-4439-A11C-50AFEBEA69A3
P2860
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Genomic analysis reveals that ...... 31 Adjuvant Trastuzumab Trial.
@ast
Genomic analysis reveals that ...... 31 Adjuvant Trastuzumab Trial.
@en
type
label
Genomic analysis reveals that ...... 31 Adjuvant Trastuzumab Trial.
@ast
Genomic analysis reveals that ...... 31 Adjuvant Trastuzumab Trial.
@en
prefLabel
Genomic analysis reveals that ...... 31 Adjuvant Trastuzumab Trial.
@ast
Genomic analysis reveals that ...... 31 Adjuvant Trastuzumab Trial.
@en
P2093
P2860
P356
P1476
Genomic analysis reveals that ...... 831 Adjuvant Trastuzumab Trial
@en
P2093
Ann E McCullough
Beiyun Chen
E Aubrey Thompson
Edith A Perez
Eric P Winer
George W Sledge
Jeanette E Eckel-Passow
Jian-Bing Fan
Julie R Gralow
P2860
P304
P356
10.1200/JCO.2014.57.6298
P407
P577
2015-01-20T00:00:00Z